British pharmaceutical giant AstraZeneca, which is selling its COVID vaccine at cost price, said on Friday that it had fallen into a loss in the third quarter.

The company posted a net loss of €1.44 billion, a statement said.

AstraZeneca said it experienced higher costs in the latest July to September period following its mega takeover of US biotech company Alexion, as well as increased research and development expenses across multiple programmes, including its COVID treatments.

The group added that revenue from its COVID vaccine totalled €1.94 billion in the year to date following delivery of around 580 million doses worldwide.

AstraZeneca's vaccine against the coronavirus pandemic was developed with the University of Oxford.

Last month, the drugs company revealed positive results from a trial of a treatment for COVID-19 symptoms.

Made from a combination of two antibodies, the AZD7442 treatment had been undergoing final clinical trials to assess its safety and efficacy.

"AstraZeneca's scientific leadership continues to provide strong revenue growth and exceptional pipeline delivery... including our long-acting antibody combination showing promise in both prevention and treatment of COVID-19," chief executive Pascal Soriot said in Friday's statement.

"The addition of Alexion furthers our commitment to bring transformative therapies to patients around the world, and I am proud of our colleagues' ongoing dedication and focus."

AstraZeneca added that group revenue soared 50 per cent in the third quarter to almost €8.64 billion.

The group completed its €34-billion takeover of Alexion earlier this year.

Since taking the helm at AstraZeneca in 2012, Soriot has pushed the group into lucrative treatments such as cancer therapies, and the Alexion takeover gives it more heft in areas such as treating blood disorders.